Home › Barrett Esophagus › NCT00288119
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Eligible cases will be defined as those patients and their family members who meet the following criteria: * Barrett's esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus. * Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent. * Ability to give informed consent, if patient is age 18 or older.
About the study
The overall objectives of this BETRNet Research Center (RC) are:
1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.
What is being tested
- Balloon Capsule Device (device)
- Endoscopy (procedure)
Sponsor: Case Western Reserve University · Participants: 2,000 · Started: Oct 1, 2005
Contact the study team
- Amitabh Chak, MD · Phone: 216-844-5385
- Wendy Brock, RN · Phone: 216-844-3853
Official record on ClinicalTrials.gov — NCT00288119
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.